Novozymes separates biopharma business
In a strategic change of direction, Denmark’s Novozymes will no longer focus on the biopharma industry. The group has already shut down activities at a Chinese factory and is now spinning off the remains into an independent company with a former Santaris exec at the strategic helm as Chairman.
BY STEFAN SINGH KAILAY
Biopharma is no longer a strategic focus area for Novozymes, which is forming an independent company dedicated to this segment, the Danish-based enzyme maker said in connection with the publication of its annual report Tuesday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
First Novozymes product approved
For abonnenter
Novozymes strikes deal with Finnish company
For abonnenter
Novozymes: More challenging than we expected
For abonnenter
